Ademi LLP Scrutinizes AtaiBeckley Buyout Deal with Eli Lilly

The proposed deal includes a Contingent Value Right worth up to $2.50 per share, tied to specific development and regulatory milestones for AtaiBeckley’s primary programs. While this could theoretically add $1.0 billion in total value, legal analysts are questioning whether the board adequately protected the interests of public shareholders during negotiations.

Central to the investigation is the transaction agreement itself, which imposes significant penalties on AtaiBeckley should the company entertain competing offers. Ademi LLP suggests these restrictive terms limit the potential for a higher bid while insiders stand to gain substantial benefits from change-of-control arrangements. The firm is currently reviewing whether the board of directors prioritized these insider interests over the broader shareholder base.